AGREEMENT INCLUDES ACTINIUM-225 (AC-225) AND LUTETIUM-177 (LU-177) TO SUPPORT ARICEUM’S THERAPEUTIC PROGRAMS

ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES

AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS

DOMESTIC STABLE ISOTOPE PROGRAM KEY TO STABILIZING SUPPLY CHAINS, ENABLING INNOVATION

CLARITY SIGNS HIGH-VOLUME COMMERCIAL-SCALE COPPER-64 SUPPLY AGREEMENT WITH NUSANO

VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently serves as the general manager and chief strategy officer for Pharmalogic, a leading contract development […]

LU-177 SHIPMENTS EXPECTED TO BEGIN EARLY 2025, FOLLOWED BY AC-225

Nusano Names Rohan Jain as Commercial General Manager.

EXECUTIVE WITH THREE DECADES OF SUCCESSFUL MULTINATIONAL OPERATIONS AND COMMERCIAL EXPERIENCE TO LEAD LAUNCH OF PROPRIETARY RADIOISOTOPE PRODUCTION PLATFORM

PROPRIETARY ION SOURCE AND BEAM TECHNOLOGY CAPABLE OF PRODUCING APPROXIMATELY 10 TIMES THE CURRENT GLOBAL SUPPLY OF ASTATINE-211